Eli Lilly's weight loss drugs removed from the FDA's shortage list
The US FDA have recently updated their drug shortage list. The recently released list shows that all dosage forms of Eli Lilly's weight-loss drug Zepbound and their diabetes drug Mounjaro are now available.
Interestingly however, these drugs have not yet been removed from the regulator’s shortage list.
Mounjaro has been on the FDA's shortage list since the latter part of 2022, and Zepbound was added in April of 2024.
The FDA works with drug companies and independent bodies to monitor the supply chain and availability of medicines, and is this instance is working closely with Eli Lilly to ensure a stable supply in all doses that can keep up with demand. The FDA clarified that additional criteria, such as fulfilling backorders and meeting demand, among others are considered before a drug is removed from the shortages list, even if all doses are currently available.
"All doses of Mounjaro and Zepbound are listed as available on the FDA's website which is consistent with our previous statements that supply would steadily improve toward the latter half of 2024," a spokesperson for Eli Lilly commented in a press statement.
The surge in demand for Mounjaro and Zepbound since their initial approvals has led Lilly to invest billions in increasing their production capacity. Danish drugmaker Novo Nordisk, which produces competing drugs Ozempic and Wegovy, is also working tirelessly to boost supply.
Initially developed for diabetes, GLP-1 therapies have demonstrated up to 20% weight reduction in clinical trials. Analysts predict that the market for these therapies could reach $150 billion in revenue by the early 2030s.
Several doses of Novo Nordisk's Ozempic and Wegovy, both semaglutides, have been on the FDA's shortage list since early 2022. Currently, all doses of Ozempic, for treatment of diabetes, are available in the USA. For Wegovy, three dosage forms continue to be in limited supply.
Source: Reuters. US FDA says all doses of Lilly's weight-loss and diabetes drug are now available. [Date accessed 05/08/2024] www.reuters.com/business/healthcare-pharmaceuticals/us-fda-says-all-doses-lillys-weight-loss-diabetes-drug-now-available-2024-08-02/
For more content on weight loss drugs on the market, see here.
Related News
-
News Global advancements in the diagnosis and treatment of rare diseases: Rare Disease Day 2024
Rare Diseases Day is celebrated on the 29th February 2024 and represents the plight of rare disease patients to gain diagnosis and access to suitable treatment. -
News Pharmaceutical industry supports COP28 health stance in joint statement
As COP28 takes place over this week in Dubai, UAE, several bodies in the pharmaceutical and health industries have come together to announce support of key movements in sustainability in the sector, and to recognise sustainability as a health issue.&nb... -
News Biden backs Cold-War measures to shore-up medical supply chains
In a recent strategy to combat rising inflation and the cost of living crisis, President Joe Biden has invoked a Cold War-era act to increase investment in a selection of medicines and supplies. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Novartis agrees for copies to be made of cancer drug to reach poorer countries
Novartis signs agreement with MPP to have generics of it's leukemia drug made so that it can be more easily distributed to the world's poorer countries. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance